{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:20:16Z","timestamp":1784233216832,"version":"3.55.0"},"reference-count":32,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"DOI":"10.1210\/en.2013-1905","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T12:54:26Z","timestamp":1411736066000},"page":"4785-4797","source":"Crossref","is-referenced-by-count":68,"title":["Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody"],"prefix":"10.1210","volume":"155","author":[{"given":"Xiaodong","family":"Li","sequence":"first","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Tian","family":"Niu","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Warmington","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin J.","family":"Asuncion","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ya","family":"Han","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stolina","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Eschenberg","sequence":"additional","affiliation":[{"name":"Biostatistics (M.J.E.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kostenuik","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Simonet","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Ominsky","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua Zhu","family":"Ke","sequence":"additional","affiliation":[{"name":"Departments of Metabolic Disorders (X.L., Q.-T.N., K.S.W., F.J.A., D.D., M.G., C.-Y.H., M.S., P.J.K., W.S.S., M.S.O., H.Z.K.), Amgen Inc, Thousand Oaks, California 91320"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2019041118070171100_B1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-84-4-393","article-title":"The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals","volume":"84","author":"Beighton","year":"1976","journal-title":"Ann Intern Med"},{"key":"2019041118070171100_B2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1259\/0007-1285-49-587-934","article-title":"The radiology of sclerosteosis","volume":"49","author":"Beighton","year":"1976","journal-title":"Br J Radiol"},{"key":"2019041118070171100_B3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1136\/jmg.25.3.200","article-title":"Sclerosteosis","volume":"25","author":"Beighton","year":"1988","journal-title":"J Med Genet"},{"key":"2019041118070171100_B4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1399-0004.2003.00036.x","article-title":"The natural history of sclerosteosis","volume":"63","author":"Hamersma","year":"2003","journal-title":"Clin Genet"},{"key":"2019041118070171100_B5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2019041118070171100_B6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet"},{"key":"2019041118070171100_B7","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"2019041118070171100_B8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B10","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","article-title":"Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model","volume":"48","author":"Tian","year":"2011","journal-title":"Bone"},{"key":"2019041118070171100_B12","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.090403","article-title":"A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis","volume":"24","author":"Eddleston","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones","volume":"26","author":"Ominsky","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr Rev"},{"key":"2019041118070171100_B15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2019041118070171100_B18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"2019041118070171100_B19","unstructured":"National Research Council (US) Committee for the Update of the Guide of the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: National Academies Press (US); 2011. http:\/\/grants.nih.gov\/grants\/olaw\/Guide-for-the-care-and-use-of-laboratory-animals.pdf."},{"key":"2019041118070171100_B20","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1\u201334) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"2019041118070171100_B21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","article-title":"RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats","volume":"23","author":"Ominsky","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/jor.1100080418","article-title":"Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats","volume":"8","author":"Turner","year":"1990","journal-title":"J Orthop Res"},{"key":"2019041118070171100_B24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bone.2010.05.032","article-title":"Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats","volume":"47","author":"Tian","year":"2010","journal-title":"Bone"},{"key":"2019041118070171100_B25","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"2019041118070171100_B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ar.1092190104","article-title":"Bone \u201cmass\u201d and the \u201cmechanostat\u201d: a proposal","volume":"219","author":"Frost","year":"1987","journal-title":"Anat Rec"},{"key":"2019041118070171100_B27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ar.1092290302","article-title":"Adaptation of diaphyseal structure to aging and decreased mechanical loading in the adult rat: a densitometric and histomorphometric study","volume":"229","author":"Li","year":"1991","journal-title":"Anat Rec"},{"key":"2019041118070171100_B28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/jbmr.5650030610","article-title":"Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading","volume":"3","author":"Pead","year":"1988","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B29","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","article-title":"Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover","volume":"26","author":"van Lierop","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/endo.132.2.8425497","article-title":"Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats","volume":"132","author":"Wronski","year":"1993","journal-title":"Endocrinology"},{"key":"2019041118070171100_B31","first-page":"S207","article-title":"Decreased osteoclastogenesis in bone marrow cells derived from ovariectomized rats treated with sclerostin antibody (Abstract)","volume":"27","author":"Liu","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2019041118070171100_B32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev Cell"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/155\/12\/4785\/10828029\/endo4785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T02:24:07Z","timestamp":1555035847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/155\/12\/4785\/2423124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2013-1905","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]}}}